<DOC>
	<DOC>NCT00367731</DOC>
	<brief_summary>After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4&lt;200cell/cu.mm. or in symptomatic HIV with CD4&lt;250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded. Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.</brief_summary>
	<brief_title>NOW Thai HAART Study</brief_title>
	<detailed_description />
	<criteria>HIV/AIDS patients. Age &gt;15 years. informed consent Not informed consent</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Neurological complications</keyword>
	<keyword>HAART</keyword>
</DOC>